Renal Cell Carcinoma
Renal Cell Carcinoma
Advertisement
James “Jim” Brugarolas, MD, PhDRenal Cell Carcinoma | April 22, 2025
Dr. Brugarolas reflects on his lab's role in developing HIF-2 inhibitors and his ongoing work to improve patient outcomes.
Read More
Emily MenendeznccRCC | April 16, 2025
An exploratory analysis revealed a strong OS advantage associated with a PD-L1 combined positive score higher than 1.
Daniel Joyce, MDRenal Cell Carcinoma Diagnostics | April 16, 2025
CA9 imaging and ZIRCON data offer new insight into managing small renal masses and supporting personalized kidney cancer care
Daniel Joyce, MDRenal Cell Carcinoma Diagnostics | April 16, 2025
Drs. Joyce and Chang discuss diagnostic strategies and future innovations in managing small renal masses.
David Braun, MD, PhDAdvanced Renal Cell Carcinoma | March 24, 2025
Drs. Beckermann and Braun reflect on key lessons from the trial, emphasizing the importance of prioritizing driver mutations.
David Braun, MD, PhDAdvanced Renal Cell Carcinoma | March 24, 2025
Drs. Beckermann and Braun break down the selection process for neoantigens in the trial for personalized RCC vaccines.
David Braun, MD, PhDAdvanced Renal Cell Carcinoma | March 24, 2025
Drs. Beckermann and Braun discuss the latter's Nature publication on a personalized neoantigen vaccine for RCC.
Emily MenendezAdvanced Renal Cell Carcinoma | March 19, 2025
Patients with mRCC on Medicare have better survival rates compared with patients on Medicaid or with no insurance.
Emily MenendezRenal Cell Carcinoma Diagnostics | March 4, 2025
A recent proof-of-concept study has further evaluated the efficacy of PSMA-guided MDT for oligometastatic RCC.
Karine Tawagi, MDRenal Cell Carcinoma | February 26, 2025
The panel concludes with future directions in RCC, including HIF inhibitors and biomarker-guided adjuvant strategies.
Karine Tawagi, MDRenal Cell Carcinoma | February 26, 2025
The panel considers how managing real-world patients on novel therapies like belzutifan presents a multitude of challenges.
Karine Tawagi, MDRenal Cell Carcinoma | February 26, 2025
The panel explains how the approval of subcutaneous nivo offers advantages in patient convenience and healthcare efficiency.
Karine Tawagi, MDRenal Cell Carcinoma | February 26, 2025
The panel weighs long-term treatment-free survival with nivo/ipi against the need for disease control with IO-TKI combos.
Karine Tawagi, MDRenal Cell Carcinoma | February 26, 2025
The panel considers the limitations of ctDNA from low tumor shedding but expresses optimism for detection technology.
Karine Tawagi, MDRenal Cell Carcinoma | February 26, 2025
The panel weighs the evolving role of biomarkers, particularly the promising blood-based biomarker KIM-1.
Emily MenendezAdvanced Renal Cell Carcinoma | February 25, 2025
The combination therapy provided similar survival rates and toxicity in an older patient population.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | February 25, 2025
Sequencing, novel therapies, and treatment combinations for refractory RCC are examined in part 5 of this discussion.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | February 25, 2025
The panel explores the evolving role of cytoreductive nephrectomy in RCC and how biomarkers shape treatment decisions.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | February 25, 2025
The panel discusses considerations for triplet therapy in RCC, new trial data, and biomarker-driven treatment strategies.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | February 25, 2025
In part 2, the panelists discuss adjuvant therapy for RCC, including biomarkers and optimizing treatment for better outcomes.
Advertisement
Advertisement